SCHEMBL19145204

SCHEMBL19145204

O=C(O)Cn1ccc2cc(-n3cc(-c4cc5cc(F)ccc5[nH]c4=O)nn3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 4/20 0.45
▸ PPARG P37231 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KDR P35968 6/20 0.36
▸ DAO P14920 1/20 0.35
▸ CXCR3 P49682 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19145598 0.90 ATM (0.38) MIFCDK5CDK5R1KDM4EALDH1A1
SCHEMBL19126839 0.86 KDR (0.47) KDRCXCR3FLT3
SCHEMBL19127012 0.80 MAPK14 (0.46) MIFCDK5CDK5R1KDM4EALDH1A1
SCHEMBL19145729 0.79 DAO (0.47) MIFCDK5CDK5R1KDM4EALDH1A1
SCHEMBL22110441 0.78 CDK5 (0.45) CDK5CDK5R1KDM4EALDH1A1NPC1
SCHEMBL30810552 0.78 CXCR3 (0.37) MIFALDH1A1KDRCXCR3KMT2A
SCHEMBL19127228 0.78 CXCR3 (0.37) MIFALDH1A1KDRCXCR3KMT2A
SCHEMBL19127082 0.78 KDM4E (0.43) CDK5CDK5R1KDM4EALDH1A1NPC1
SCHEMBL19145552 0.77 KDR (0.48) CDK5CDK5R1KDM4EALDH1A1NPC1
SCHEMBL19126535 0.77 ALDH1A1 (0.47) MIFCDK5CDK5R1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028687-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-26 — — US disclosed
US-11186562-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2021-11-30 — — US disclosed
US-11174241-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2021-11-16 — — US disclosed
US-20200190054-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-18 — — US disclosed
US-20200190055-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-18 — — US disclosed
US-10669251-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2020-06-02 — — US disclosed
US-20190023685-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2019-01-24 — — US disclosed
WO-2017121444-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2017-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174241-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-20190023685-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-20200190054-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-20230028687-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-20200190055-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-10669251-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885
US-11186562-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 MIF 4801/4885PPARG 4672/4885CDK5 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback